Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Claris Bio","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$57.0 million","upfrontCash":"Undisclosed","newsHeadline":"Claris Bio Emerges from Stealth with a New Investor and Prepares for Next Development Stage with Late-Stage Data Expected in 1H24","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Claris Bio

    Menu

    Claris Bio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Claris Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Claris Bio Emerges from Stealth with a New Investor and Prepares for Next Development Stage with Late-Stage Data Expected in 1H24

              Details:

              The net proceeds will be used to advance CSB-001 (oremepermin alfa), a topical ocular biologic solution of dHGF, which targets the complete healing of the cornea surface in eyes with Neurotrophic Keratopathy (NK).

              Lead Product(s): Oremepermin Alfa

              Therapeutic Area: Ophthalmology Product Name: CSB-001

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Novo Holdings

              Deal Size: $57.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing January 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY